These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32019769)

  • 1. Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS.
    Engel S; Steffen F; Uphaus T; Scholz-Kreisel P; Zipp F; Bittner S; Luessi F
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32019769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
    Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
    EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
    J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases.
    Ziaei A; Nasr Z; Hart J; Francisco C; Rutatangwa A; Leppert D; Kuhle J; Flanagan E; Waubant E
    Mult Scler Relat Disord; 2023 Jun; 74():104704. PubMed ID: 37031551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome.
    Fabis-Pedrini MJ; Kuhle J; Roberts KMA; Trend S; Jones AP; Maceski A; Carroll WM; Lucas RM; Mastaglia FL; Hart PH; Kermode AG
    Brain Behav; 2022 Feb; 12(2):e2494. PubMed ID: 35084124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.
    Sainz-Amo R; Rodero Romero A; Monreal E; Chico García JL; Fernández Velasco JI; Villarrubia N; Veiga González JL; Sainz de la Maza S; Rodríguez Jorge F; Masjuan J; Costa-Frossard L; Villar LM
    Front Immunol; 2024; 15():1454474. PubMed ID: 39224593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of radiologic disease activity by serum neurofilaments in MS.
    Uher T; Schaedelin S; Srpova B; Barro C; Bergsland N; Dwyer M; Tyblova M; Vodehnalova K; Benkert P; Oechtering J; Leppert D; Naegelin Y; Krasensky J; Vaneckova M; Kubala Havrdova E; Kappos L; Zivadinov R; Horakova D; Kuhle J; Kalincik T
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32273481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    Dietmann AS; Kruse N; Stork L; Gloth M; Brück W; Metz I
    J Neurol; 2023 Mar; 270(3):1416-1429. PubMed ID: 36372867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.
    Bjornevik K; Munger KL; Cortese M; Barro C; Healy BC; Niebuhr DW; Scher AI; Kuhle J; Ascherio A
    JAMA Neurol; 2020 Jan; 77(1):58-64. PubMed ID: 31515562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
    Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C
    Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.
    Bava CI; Valentino P; Malucchi S; Bottero R; Martire S; Sapio AD; Bertolotto A
    Mult Scler Relat Disord; 2024 Aug; 88():105748. PubMed ID: 38959590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders.
    Liu C; Zhao L; Fan P; Ko H; Au C; Ng A; Au L; Wong A; Kermode AG; Mok V; Yan Y; Qiu W; Lau AY
    J Clin Neurosci; 2021 Jan; 83():108-111. PubMed ID: 33317883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Fox RJ; Cree BAC; de Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Singh CM; Altincatal A; Belviso N; Avila RL; Ho PR; Su R; Engle R; Sangurdekar D; de Moor C; Fisher E; Kieseier BC; Rudick RA
    Neurology; 2024 May; 102(9):e209357. PubMed ID: 38648580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS.
    Engel S; Friedrich M; Muthuraman M; Steffen F; Poplawski A; Groppa S; Bittner S; Zipp F; Luessi F
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):. PubMed ID: 31454774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies.
    Castellazzi M; Contini C; Tamborino C; Fasolo F; Roversi G; Seraceni S; Rizzo R; Baldi E; Tola MR; Bellini T; Granieri E; Fainardi E
    J Neuroinflammation; 2014 Nov; 11():188. PubMed ID: 25391491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Bsteh G; Berek K; Hegen H; Teuchner B; Buchmann A; Voortman MM; Auer M; Wurth S; Zinganell A; Di Pauli F; Deisenhammer F; Khalil M; Berger T
    Mult Scler; 2020 Nov; 26(13):1682-1690. PubMed ID: 31668116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.